Neurocrine Biosciences (NBIX): Reiterate Top Mid Cap Pick - BMO

September 23, 2016 7:10 AM EDT
Get Alerts NBIX Hot Sheet
Price: $41.62 -1%

Rating Summary:
    15 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade NBIX Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on shares of Neurocrine Bio. (NASDAQ: NBIX) after the company released abstracts for the American Society of Reproductive Medicine conference (October 15-19).

The analyst stated that the abstracts reinforce elagolix's strong efficacy profile in women with endometriosis, showing significant improvements on endometrial-associated pain, endometrial morphology, and quality of life observed on treatment. He believes the data continues to support approval for elagolix’s low- and high-doses, and his $1.0B peak sales estimate in endometriosis, with an additional blockbuster opportunity in uterine fibroids ($2.7B peak sales).

No change to the price target of $66.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $54.16 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

BMO Capital

Add Your Comment